The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Open accessAbstract
TP53 is the most commonly mutated gene in human cancer with over 100,000 literature citations in PubMed. This is a heavily studied pathway in cancer biology and oncology with a history that dates back to 1979 when p53 was discovered. The p53 pathway is a complex cellular stress response network with multiple diverse inputs and downstream outputs relevant to its role as a tumor suppressor pathway. While inroads have been made in understanding the biology and signaling in the p53 pathway, the p53 family, transcriptional readouts, and effects of an array of mutants, the pathway remains challenging in the realm of clinical translation. While the role of mutant p53 as a prognostic factor is recognized, the therapeutic modulation of its wild-type or mutant activities remain a work-in-progress. This review covers current knowledge about the biology, signaling mechanisms in the p53 pathway and summarizes advances in therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.005 · Cited by 436
Retractedp63 and p73 Transcriptionally Regulate Genes Involved in DNA Repair
Lin, Y., Sengupta, S., Gurdziel, K., Bell, G. W., Jacks, T., & Flores, E. R. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000680 · Cited by 137
RetractedTransactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
RetractedWAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Self-citationCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Stöckl, S., Göttl, C., Grifka, J., & Grässel, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350089 · Cited by 4,656
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Self-citationp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,225
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Self-citationKastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
p53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,123
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048
A role for ATR in the DNA damage-induced phosphorylation of p53
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development · doi:10.1101/gad.13.2.152 · Cited by 1,046
Inhibition of cyclin-dependent kinases by p21.
Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., & Swindell, E. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.4.387 · Cited by 1,023
Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 990
p73 is a human p53-related protein that can induce apoptosis
Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
p53 represses c-Myc through induction of the tumor suppressor miR-145
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K., & Mo, Y.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808042106 · Cited by 841
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
p53 is regulated by the lysine demethylase LSD1
Huang, J., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., et al. (2007) · Nature · doi:10.1038/nature06092 · Cited by 807
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage
Flores, E. R., Tsai, K. Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., & Jacks, T. (2002) · Nature · doi:10.1038/416560a · Cited by 802
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 730
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Tang, Y., Luo, J., Zhang, W., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.021 · Cited by 727
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
Eliyahu, D., Raz, A., Gruss, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 717
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Harris, C. C. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1442 · Cited by 680
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 653
SUMO-1 modification activates the transcriptional response of p53
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Midgley, C. A., Lane, D. P., & Hay, R. T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6455 · Cited by 639
GADD45 induction of a G 2 /M cell cycle checkpoint
Wang, X. W., Zhan, Q., Coursen, J. D., Khan, M. A., Kontny, H. U., Yu, L., Hollander, M. C., O’Connor, P. M., Fornace, A. J., & Harris, C. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3706 · Cited by 634
Repression of p53 activity by Smyd2-mediated methylation
Huang, J., Perez-Burgos, L., Placek, B. J., Sengupta, R., Richter, M., Dorsey, J. A., Kubicek, S., Opravil, S., Jenuwein, T., & Berger, S. L. (2006) · Nature · doi:10.1038/nature05287 · Cited by 624
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.
Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13777 · Cited by 583
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2
Ito, A., Lai, C.-H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., & Yao, T.-P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1331 · Cited by 582
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity
Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570
p63 protects the female germ line during meiotic arrest
Suh, E.-K., Yang, A., Kettenbach, A., Bamberger, C., Michaelis, A. H., Zhu, Z., Elvin, J. A., Bronson, R. T., Crum, C. P., & McKeon, F. (2006) · Nature · doi:10.1038/nature05337 · Cited by 549
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
Kim, T., Veronese, A., Pichiorri, F., Lee, T. J., Jeon, Y.-J., Volinia, S., Pineau, P., Marchio, A., Palatini, J., Suh, S.-S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110235 · Cited by 514
p63 expression profiles in human normal and tumor tissues.
Como, C. J. D., Urist, M. J., Babayan, I., Drobnjak, M., Hedvat, C. V., Teruya‐Feldstein, J., Kamal, P., Hoos, A., & Cordon‐Cardo, C. (2002) · PubMed · Cited by 511
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
China Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489
p63 and p73: Roles in Development and Tumor Formation
Moll, U. M., & Slade, N. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.371.2.7 · Cited by 486
Identification of a novel p53 functional domain that is necessary for efficient growth suppression
Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 471
Mechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
Espinosa, J. M., & Emerson, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00283-0 · Cited by 439
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition
Kim, N. H., Kim, H. S., Li, X.-Y., Lee, I., Choi, H.-S., Kang, S. E., Cha, S. Y., Ryu, J. K., Yoon, D., Fearon, E. R., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201103097 · Cited by 432
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis
Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., Huso, D., & Lowenstein, C. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911082107 · Cited by 430
BID regulation by p53 contributes to chemosensitivity
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420
Self-citationDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Clinical Outcomes and Correlates of TP53 Mutations and Cancer
Robles, A. I., & Harris, C. C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001016 · Cited by 394
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation
Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W. X., Corazzari, M., Knight, R. A., Green, D. R., Thompson, C., & Vousden, K. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307469200 · Cited by 368
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354
Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215
Georges, S. A., Biery, M. C., Kim, S.-Y., Schelter, J. M., Guo, J., Chang, A. N., Jackson, A. L., Carleton, M. O., Linsley, P. S., Cleary, M. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1846 · Cited by 348
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
Fischer, M., Grossmann, P., Padi, M., & DeCaprio, J. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw523 · Cited by 330
Characterization of the human p53 gene.
Lamb, P., & Crawford, L. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1379 · Cited by 327
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
The polyproline region of p53 is required to activate apoptosis but not growth arrest
Sakamuro, D., Sabbatini, P., White, E., & Prendergast, G. C. (1997) · Oncogene · doi:10.1038/sj.onc.1201263 · Cited by 316
Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
Venot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 291
p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection
Goodrum, F. D., & Ornelles, D. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9479-9490.1998 · Cited by 289
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Hanel, W., Marchenko, N., Xu, S., Xiaofeng Yu, S., Weng, W., & Moll, U. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.17 · Cited by 283
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283
A variation in the structure of the protein-coding region of the human p53 gene
Buchman, V. L., Chumakov, P. M., Ninkina, N. N., Samarina, O. P., & Georgiev, G. P. (1988) · Gene · doi:10.1016/0378-1119(88)90196-5 · Cited by 278
p63 and p73 in human cancer: defining the network
DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 266
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
Saito, S., Yamaguchi, H., Higashimoto, Y., Chao, C., Xu, Y., Fornace, A. J., Appella, E., & Anderson, C. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305135200 · Cited by 254
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Tomita, Y., Marchenko, N., Erster, S., Nemajerova, A., Dehner, A., Klein, C., Pan, H., Kessler, H., Pancoska, P., & Moll, U. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507611200 · Cited by 248
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Chen, S., Wu, J.-L., Liang, Y., Tang, Y.-G., Song, H.-X., Wu, L.-L., Xing, Y.-F., Yan, N., Li, Y.-T., Wang, Z.-Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.013 · Cited by 241
Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein.
Crawford, L. V., Pim, D. C., Gurney, E. G., Goodfellow, P., & Taylor-Papadimitriou, J. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.41 · Cited by 236
Small molecule induced reactivation of mutant p53 in cancer cells
Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I. S., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 234
Somatic TP53 Mutations in the Era of Genome Sequencing
Hainaut, P., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 231
Zhang, J., Sun, Q., Zhang, Z., Ge, S., Han, Z.-G., & Chen, W.-T. (2013) · Oncogene · doi:10.1038/onc.2012.28 · Cited by 224
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
p53-family proteins and their regulators: hubs and spokes in tumor suppression
Collavin, L., Lunardi, A., & Del Sal, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.35 · Cited by 220
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.
Zakut-Houri, R., Bienz-Tadmor, B., Givol, D., & Oren, M. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03768.x · Cited by 218
Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210
Jin, S., Tong, T., Fan, W., Fan, F., Antinore, M. J., Zhu, X., Mazzacurati, L., Li, X., Petrik, K. L., Rajasekaran, B., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1206034 · Cited by 207
Halazonetis, T. D., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06199.x · Cited by 205
Michalak, E. M., Villunger, A., Adams, J. M., & Strasser, A. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.16 · Cited by 205
Integration of TGF-ß and Ras/MAPK Signaling Through p53 Phosphorylation
Cordenonsi, M., Montagner, M., Adorno, M., Zacchigna, L., Martello, G., Mamidi, A., Soligo, S., Dupont, S., & Piccolo, S. (2007) · Science · doi:10.1126/science.1135961 · Cited by 203
Chaperone-mediated autophagy degrades mutant p53
Vakifahmetoglu-Norberg, H., Kim, M., Xia, H.-G., Iwanicki, M. P., Ofengeim, D., Coloff, J. L., Pan, L., Ince, T. A., Kroemer, G., Brugge, J. S., et al. (2013) · Genes & Development · doi:10.1101/gad.220897.113 · Cited by 203
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199
Death and decoy receptors and p53-mediated apoptosis
Sheikh, M., & Fornace, A. (2000) · Leukemia · doi:10.1038/sj.leu.2401865 · Cited by 199
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198
Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential
Kazanets, A., Shorstova, T., Hilmi, K., Marques, M., & Witcher, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.04.001 · Cited by 195
Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194
Structure, Function, and Aggregation of the Zinc-Free Form of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2003) · Biochemistry · doi:10.1021/bi026635n · Cited by 191
Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191
Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization
Peng, Y., Chen, L., Li, C., Lu, W., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102817200 · Cited by 183
p53 Family members p63 and p73 are SAM domain‐containing proteins
Thanos, C. D., & Bowie, J. U. (1999) · Protein Science · doi:10.1110/ps.8.8.1708 · Cited by 169
Stewart, Z. A., Leach, S. D., & Pietenpol, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.205 · Cited by 168
Baptiste, N., Friedlander, P. A., Chen, X., & Prives, C. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205015 · Cited by 168
Oncosuppressive role of p53‐induced miR‐205 in triple negative breast cancer
Piovan, C., Palmieri, D., Di Leva, G., Braccioli, L., Casalini, P., Nuovo, G., Tortoreto, M., Sasso, M., Plantamura, I., Triulzi, T., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.03.003 · Cited by 166
Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G., & Schuetz, J. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.11037 · Cited by 163
p53 β-hydroxybutyrylation attenuates p53 activity
Liu, K., Li, F., Sun, Q., Lin, N., Han, H., You, K., Tian, F., Mao, Z., Li, T., Tong, T., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1463-y · Cited by 163
Rotter, V. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.9.2613 · Cited by 161
Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18709 · Cited by 160
Phosphorylation of p21 in G2/M Promotes Cyclin B-Cdc2 Kinase Activity
Dash, B. C., & El‐Deiry, W. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3364-3387.2005 · Cited by 160
Self-citationTeufel, D. P., Bycroft, M., & Fersht, A. R. (2009) · Oncogene · doi:10.1038/onc.2009.71 · Cited by 159
p53 Isoforms: An Intracellular Microprocessor?
Khoury, M. P., & Bourdon, J.-C. (2011) · Genes & Cancer · doi:10.1177/1947601911408893 · Cited by 159
Fontemaggi, G., Kela, I., Amariglio, N., Rechavi, G., Krishnamurthy, J., Strano, S., Sacchi, A., Givol, D., & Blandino, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205573200 · Cited by 155
MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function
Donzelli, S., Fontemaggi, G., Fazi, F., Agostino, S. D., Padula, F., Biagioni, F., Muti, P. C., Strano, S., & Blandino, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.190 · Cited by 154
Tumor suppressive role for kinases phosphorylating p53 in DNA damage‐induced apoptosis
Yogosawa, S., & Yoshida, K. (2018) · Cancer Science · doi:10.1111/cas.13792 · Cited by 153
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 152
Salim, K. Y., Maleki Vareki, S., Danter, W. R., San-Marina, S., & Koropatnick, J. (2106) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 148
Overproduction of p53 antigen makes established cells highly tumorigenic
Eliyahu, D., Michalovitz, D., & Oren, M. (1985) · Nature · doi:10.1038/316158a0 · Cited by 146
Structural Basis for p300 Taz2-p53 TAD1 Binding and Modulation by Phosphorylation
Feng, H., Jenkins, L. M. M., Durell, S. R., Hayashi, R., Mazur, S. J., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., et al. (2009) · Structure · doi:10.1016/j.str.2008.12.009 · Cited by 145
Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143
The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis
Takimoto, R., Wang, W., Dicker, D. T., Rastinejad, F., Lyssikatos, J. P., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.1.41 · Cited by 142
Self-citationSer46 Phosphorylation Regulates p53-Dependent Apoptosis and Replicative Senescence
Feng, L., Hollstein, M., & Xu, Y. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3526 · Cited by 140
p53: emerging roles in stem cells, development and beyond
Jain, A. K., & Barton, M. C. (2018) · Development · doi:10.1242/dev.158360 · Cited by 135
MDM2-ARF complex regulates p53 sumoylation
Chen, L., & Chen, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206851 · Cited by 134
Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2
Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 130
Rodriguez, O. C., Choudhury, S., Kolukula, V. K., Vietsch, E. E., Catania, J., Preet, A., Reynoso, K., Bargonetti, J., Wellstein, A., Albanese, C., et al. (2012) · Cell Cycle · doi:10.4161/cc.22778 · Cited by 129
Molecular basis of Pirh2-mediated p53 ubiquitylation
Sheng, Y., Laister, R. C., Lemak, A. S., Wu, B., Tai, E., Duan, S., Lukin, J. A., Sunnerhagen, M., Srisailam, S., Karra, M., et al. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1521 · Cited by 129
Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo
Whitesell, L. J., Sutphin, P. D., An, W. G., Schulte, T. W., Blagosklonny, M. V., & Neckers, L. (1997) · Oncogene · doi:10.1038/sj.onc.1201120 · Cited by 127
Wu, S., & Chiang, C. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.83 · Cited by 125
Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration
Yeudall, W. A., Vaughan, C. A., Miyazaki, H., Ramamoorthy, M., Choi, M.-Y., Chapman, C. G., Wang, H., Black, E., Bulysheva, A. A., Deb, S. P., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr270 · Cited by 124
Lindemann, A., Patel, A. A., Silver, N. L., Tang, L., Liu, Z., Wang, L., Tanaka, N., Rao, X., Takahashi, H., Maduka, N. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0096 · Cited by 124
Anderson, M. E., Woelker, B., Reed, M. J., Wang, P., & Tegtmeyer, P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6255 · Cited by 120
Laptenko, O., Shiff, I., Freed-Pastor, W., Zupnick, A., Mattia, M., Freulich, E., Shamir, I., Kadouri, N., Kahan, T., Manfredi, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.015 · Cited by 119
Functional interplay between MDM2, p63/p73 and mutant p53
Stindt, M., Muller, P. A. J., Ludwig, R., Kehrloesser, S., Dötsch, V., & Vousden, K. H. (2014) · Oncogene · doi:10.1038/onc.2014.359 · Cited by 119
Bayle, J. H., Elenbaas, B., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5729 · Cited by 119
Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage
Shirangi, T. R., Zaika, A., & Moll, U. M. (2002) · The FASEB Journal · doi:10.1096/fj.01-0617fje · Cited by 115
Zhang, S., Zhou, L., Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Warfel, N. A., Kline, C. L. B., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1079 · Cited by 114
Self-citationHelton, E. S., Zhu, J., & Chen, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507964200 · Cited by 114
Хромова, Н. В., Kopnin, P., Степанова, Е. В., Agapova, L. S., & Kopnin, B. P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.049 · Cited by 110
Xu, J., & Morris, G. F. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.12 · Cited by 110
Expression of SUMO-2/3 Induced Senescence through p53- and pRB-mediated Pathways
Li, T., Santockyte, R., Shen, R., Tekle, E., Wang, G., Yang, D. C. H., & Chock, P. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608236200 · Cited by 109
Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain
Pietsch, E. C., Perchiniak, E. M., Canutescu, A. A., Wang, G., Dunbrack, R. L., & Murphy, M. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710539200 · Cited by 108
Improving cancer therapy by non-genotoxic activation of p53
Laín, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 106
Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000104 · Cited by 103
Yi, Y. W., Kang, H. J., Kim, H. J., Kong, Y., Brown, M. L., & Bae, I. (2013) · Oncotarget · doi:10.18632/oncotarget.1070 · Cited by 102
MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame
Mandke, P., Wyatt, N., Fraser, J., Bates, B., Berberich, S. J., & Markey, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042034 · Cited by 100
Mutant p53: One, No One, and One Hundred Thousand
Walerych, D., Lisek, K., & Sal, G. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00289 · Cited by 100
Distinct pattern of p53 phosphorylation in human tumors
Minamoto, T., Buschmann, T., Habelhah, H., Matusevich, E., Tahara, H., Børresen‐Dale, A., Harris, C. C., Sidransky, D., & Ronai, Z. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204458 · Cited by 100
Polotskaia, A., Xiao, G., Reynoso, K., Martin, C., Qiu, W., Hendrickson, R. C., & Bargonetti, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416318112 · Cited by 94
Al-Bahlani, S. M., Fraser, M. E., Wong, A. Y. C., Sayan, B. S., Bergeron, R., Melino, G., & Tsang, B. K. (2011) · Oncogene · doi:10.1038/onc.2011.134 · Cited by 93
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
Chen, G., Zhang, S. J., He, X., Liu, S., Ma, C., & Zou, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s50483 · Cited by 89
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Hong, B., Prabhu, V. V., Zhang, S., van den Heuvel, A. P. J., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0955 · Cited by 87
Self-citationSer392 Phosphorylation Regulates the Oncogenic Function of Mutant p53
Yap, D., Hsieh, J.-K., Zhong, S., Heath, V., Gusterson, B. A., Crook, T., & Lü, X. (2004) · Cancer Research · doi:10.1158/0008-5472.can-1305-2 · Cited by 87
Lányi, Á., Deb, D., Seymour, R. C., Ludes-Meyers, J. H., Subler, M. A., & Deb, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201857 · Cited by 87
Phosphorylation and hsp90 Binding Mediate Heat Shock Stabilization of p53
Wang, C., & Chen, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206697200 · Cited by 86
Wagner, A. J., Chugh, R. K., Rosen, L. S., Morgan, J. A., George, S., Gordon, M. S., Dunbar, J., Normant, E., Grayzel, D., & Demetri, G. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0953 · Cited by 85
Böhlig, L., Friedrich, M., & Engeland, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq796 · Cited by 85
Rotter, V., Boss, M. A., & Baltimore, D. (1981) · Journal of Virology · doi:10.1128/jvi.38.1.336-346.1981 · Cited by 82
p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation
Itahana, Y., Ke, H., & Zhang, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805696200 · Cited by 82
Ruaro, E. M., Collavin, L., Del Sal, G., Haffner, R., Oren, M., Levine, A. J., & Schneider, C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4675 · Cited by 82
Role of p63 in cancer development
Graziano, V., & Laurenzi, V. D. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.04.002 · Cited by 82
Jenkins, J. R., Rudge, K., Redmond, S. M. S., & Wade‐Evans, A. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.14.5609 · Cited by 80
Oncogenic Intra-p53 Family Member Interactions in Human Cancers
Ferraiuolo, M. A., Agostino, S. D., Blandino, G., & Strano, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00077 · Cited by 80
Cited by
Cell cycle regulation: p53-p21-RB signaling
Engeland, K. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00988-z · Cited by 1,274
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Metadata
- Authors
- Hernández Borrero, L. J., & El-Deiry, W. S.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 1876
- Issue
- 1
- Pages
- 188556
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3159454489
- Cited by
- 748
- References
- 236
- FWCI
- 32.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.